Neuronetics Inc 's Cash & cash equivalent grew by 31.55 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Neuronetics Inc 's Quick Ratio to 0.88, Quick Ratio remained below Neuronetics Inc average.

Within Medical Equipment & Supplies industry 112 other companies have achieved higher Quick Ratio than Neuronetics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1921, from total ranking in the first quarter 2026 at 1959.

Explain Quick Ratio?
How much Cash & cash equivalents STIM�s has?
What are STIM�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

STIM Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	25.9 %	14.78 %	-5.72 %	13.13 %	-20.83 %
Y / Y Cash & cash equivalent Change	42.81 %	-6.23 %	84.92 %	65.19 %	-59.03 %
Quick Ratio MRQ	0.88	0.83	1.37	1.48	0.78
STIM's Total Ranking	# 1921	# 1959	# 1510	# 1247	# 1627
Seq. Current Liabilities Change	23.82 %	-8.4 %	6.87 %	3.87 %	12.89 %
Seq. Cash & cash equivalent Change	31.55 %	-44.44 %	-0.98 %	97.33 %	-13.62 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 113
Healthcare Sector	# 649
Overall Market	# 1921

Quick Ratio Statistics
High	Average	Low
11.77	3.43	0.7
(Mar 31 2021)		(Dec 31 2024)

Financial Statements
Neuronetics Inc 's Current Liabilities	$ 28 Millions	Visit STIM's Balance sheet
Neuronetics Inc 's Cash & cash equivalent	$ 25 Millions	Visit STIM's Balance sheet
Source of STIM's Sales		Visit STIM's Sales by Geography

Cumulative Neuronetics Inc 's Quick Ratio

STIM's Quick Ratio for the trailling 12 Months

STIM Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	11.13 %	-1.86 %	1.74 %	12.95 %	18.56 %
Y / Y Cash & cash equivalent TTM Growth	46.09 %	2.78 %	-18.04 %	-46.98 %	-58.57 %
Quick Ratio TTM	1.13	1.12	1.17	0.98	0.86
Total Ranking TTM	# 3961	# 4005	# 2507	# 3324	# 3038
Seq. Current Liabilities TTM Growth	6.22 %	3.25 %	-1.64 %	3.03 %	-6.2 %
Seq. Cash & cash equivalent TTM Growth	7.12 %	-1.19 %	17.3 %	17.66 %	-24.63 %

Quick ratio ranking by company, industry and sector >> Back to STIM Financial Strength Comparisons >> Go to Compare STIM Quick Ratio to its Competitors

News about Neuronetics Inc Quick Ratio

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4): A Pioneering Approach to Attracting Top Talent and Encouraging Innovation

Neuronetics, a leading medical technology company specializing in creating innovative solutions for patients with neurohealth disorders, recently announced the issuance of Restricted Stock Units (RSUs) as inducement awards to sixteen new non-executive employees. These awards, totaling 55,200 shares, were granted to the employees in accordance with NASDAQ Listing Rule 5635(c)(4) and were approved by Neuronetics Compensation Committee as essential inducements to attract and retain top talent at the company.
Neuronetics commitment to improving the lives of individuals suffering from neurohealth disorders is evident through their unwavering dedication in developing and marketing groundbreaking medical products. By providing effective treatments and groundbreaking technologies, the company aims to enhance the quality of life for patients in need of neurological care.

Neuronetics Secures $90 Million Debt Facility with Perceptive Advisors, Improving Financial Health

In a recent announcement, Neuronetics, Inc. (NASDAQ: STIM) revealed that it has entered into a debt facility of up to $90 million with Perceptive Advisors LLC. This senior secured credit facility will provide Neuronetics with much-needed financial support as it continues to develop innovative medical technologies to improve the quality of life for patients with neurohealth disorders.
One particular highlight of this deal is the significant decrease in Neuronetics current liabilities, allowing for an improvement in the Quick Ratio to 3.5. Despite some fluctuations in the company s financial metrics, this partnership with Perceptive Advisors bodes well for Neuronetics future growth and success.

On the trailing twelve months basis STIM Cash & cash equivalent soared by 42.81 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Neuronetics Inc 's Quick Ratio to 1.13, Quick Ratio remained below STIM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 201 other companies have achieved higher Quick Ratio than Neuronetics Inc . While Quick Ratio overall ranking has improved so far to 3961, from total ranking during the twelve months ending first quarter 2026 at 4005.

Explain Quick Ratio?
How much Cash & cash equivalents STIM�s has?
What are STIM�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 202
Healthcare Sector	# 893
Within the Market	# 3961

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.77	2.76	0.19
(Jun 30 2019)		(Jun 30 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Electromed Inc	2.35	$ 20.450 Millions	$ 8.714 Millions
EBR Systems, Inc.	2.18	$ 113.533 Millions	$ 52.023 Millions
Medinotec Inc	2.15	$ 2.519 Millions	$ 1.171 Millions
Atricure Inc	2.05	$ 167.786 Millions	$ 81.916 Millions
Tactile Systems Technology Inc	1.83	$ 69.853 Millions	$ 38.253 Millions
Tandem Diabetes Care Inc	1.80	$ 455.996 Millions	$ 253.005 Millions
Inspire Medical Systems inc	1.79	$ 127.761 Millions	$ 71.282 Millions
Warby Parker Inc	1.79	$ 292.674 Millions	$ 163.480 Millions
Capsovision Inc	1.76	$ 9.077 Millions	$ 5.158 Millions
Anika Therapeutics Inc	1.73	$ 38.412 Millions	$ 22.147 Millions
Genedx Holdings Corp	1.71	$ 132.548 Millions	$ 77.648 Millions
Beta Bionics Inc	1.70	$ 44.318 Millions	$ 26.017 Millions
Merit Medical Systems Inc	1.70	$ 450.906 Millions	$ 264.933 Millions
Seastar Medical Holding Corp	1.60	$ 6.959 Millions	$ 4.353 Millions
Tela Bio Inc	1.59	$ 30.424 Millions	$ 19.080 Millions
Conexeu Sciences Inc	1.55	$ 1.971 Millions	$ 1.272 Millions
Inogen Inc	1.49	$ 105.539 Millions	$ 70.864 Millions
Dariohealth Corp	1.49	$ 14.254 Millions	$ 9.578 Millions
Myomo Inc	1.45	$ 15.686 Millions	$ 10.805 Millions
Envoy Medical Inc	1.43	$ 19.679 Millions	$ 13.807 Millions
Nephros Inc	1.40	$ 4.697 Millions	$ 3.344 Millions
Envista Holdings Corporation	1.39	$ 1,125.600 Millions	$ 807.300 Millions
Medtronic Plc	1.36	$ 16,068.000 Millions	$ 11,799.000 Millions
Sanara Medtech Inc	1.31	$ 16.421 Millions	$ 12.494 Millions
Globus Medical Inc	1.24	$ 595.142 Millions	$ 479.347 Millions
Lucid Diagnostics Inc	1.21	$ 33.404 Millions	$ 27.516 Millions
Sintx Technologies Inc	1.21	$ 3.590 Millions	$ 2.977 Millions
Vaso Corporation	1.17	$ 38.291 Millions	$ 32.863 Millions
Koru Medical Systems Inc	1.15	$ 8.288 Millions	$ 7.180 Millions
Precision Optics Corporation Inc	1.11	$ 9.841 Millions	$ 8.828 Millions

Date modified: 2026-09-12T06:23:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.